95 related articles for article (PubMed ID: 27156633)
41. Validation of the Mantle Cell Lymphoma International Prognostic Index: A single-center retrospective analysis.
Smith SD; Hsi E; Bolwell B; Pohlman B; Dean R; Effinger M; Maggiotto A; Sweetenham J
Am J Hematol; 2010 Jun; 85(6):454-6. PubMed ID: 20513126
[TBL] [Abstract][Full Text] [Related]
42. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.
de Guibert S; Jaccard A; Bernard M; Turlure P; Bordessoule D; Lamy T
Haematologica; 2006 Mar; 91(3):425-6. PubMed ID: 16531272
[TBL] [Abstract][Full Text] [Related]
43. Mantle cell lymphoma: clinicopathologic features and treatments.
Kauh J; Baidas SM; Ozdemirli M; Cheson BD
Oncology (Williston Park); 2003 Jun; 17(6):879-91, 896; discussion 896-8. PubMed ID: 12846128
[TBL] [Abstract][Full Text] [Related]
44. Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma.
Cheah CY; Milgrom S; Chihara D; Gombos DS; Pinnix CC; Dabaja BS; Fowler NH
Neuro Oncol; 2016 Apr; 18(4):575-81. PubMed ID: 26487691
[TBL] [Abstract][Full Text] [Related]
45. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
[TBL] [Abstract][Full Text] [Related]
46. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
47. [Current treatment strategy in mantle cell lymphoma].
Ogura M
Nihon Rinsho; 2014 Mar; 72(3):499-511. PubMed ID: 24724411
[TBL] [Abstract][Full Text] [Related]
48. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S
Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 24563925
[TBL] [Abstract][Full Text] [Related]
49. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S
Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 23949376
[TBL] [Abstract][Full Text] [Related]
50. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
51. Outcome of deferred initial therapy in mantle-cell lymphoma.
Martin P; Chadburn A; Christos P; Weil K; Furman RR; Ruan J; Elstrom R; Niesvizky R; Ely S; Diliberto M; Melnick A; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
J Clin Oncol; 2009 Mar; 27(8):1209-13. PubMed ID: 19188674
[TBL] [Abstract][Full Text] [Related]
52. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).
García-Noblejas A; Cannata-Ortiz J; Conde E; González Barca E; Gutiérrez N; Rojas R; Vidal MJ; Ramírez MJ; Jiménez-Ubieto A; García-Ruiz JC; Sancho JM; López A; Ríos Rull P; Novelli S; Albo C; Debén G; López-Guillermo A; Nicolás C; González de Villambrosia S; Mercadal S; Martín García-Sancho A; Arranz R
Ann Hematol; 2017 Aug; 96(8):1323-1330. PubMed ID: 28536895
[TBL] [Abstract][Full Text] [Related]
53. Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: Findings from Texas and national SEER areas.
Fu S; Wang M; Li R; Lairson DR; Zhao B; Du XL
Cancer Epidemiol; 2019 Feb; 58():89-97. PubMed ID: 30528835
[TBL] [Abstract][Full Text] [Related]
54. Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
Guidot DM; Switchenko JM; Nastoupil LJ; Koff JL; Blum KA; Maly J; Flowers CR; Cohen JB
Leuk Lymphoma; 2018 Apr; 59(4):888-895. PubMed ID: 28797213
[TBL] [Abstract][Full Text] [Related]
55. Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.
Augustin A; Le Gouill S; Gressin R; Bertaut A; Monnereau A; Woronoff AS; Trétarre B; Delafosse P; Troussard X; Moreau A; Hermine O; Maynadié M
J Cancer Res Clin Oncol; 2018 Apr; 144(4):629-635. PubMed ID: 29022078
[TBL] [Abstract][Full Text] [Related]
56. Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study.
Schreiber S; Hoellein A; Decker T; Jilg S; Dreyling M; Peschel C; Keller U
Leuk Lymphoma; 2015; 56(11):3227-9. PubMed ID: 25754578
[No Abstract] [Full Text] [Related]
57. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.
Calzada O; Switchenko JM; Maly JJ; Blum KA; Grover N; Mathews S; Park SI; Gordon M; Danilov A; Epperla N; Fenske TS; Hamadani M; Flowers CR; Cohen JB
Leuk Lymphoma; 2018 Dec; 59(12):2862-2870. PubMed ID: 29912594
[TBL] [Abstract][Full Text] [Related]
58. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.
Visco C; Tisi MC; Evangelista A; Di Rocco A; Zoellner AK; Zilioli VR; Hohaus S; Sciarra R; Re A; Tecchio C; Chiappella A; Morello L; Gini G; Nassi L; Perrone T; Molinari AL; Fabbri A; Cox MC; Finolezzi E; Ferrero S; Puccini B; Alvarez De Celis I; Arcari A; Marino D; Merli M; Piazza F; Gentile M; Pelosini M; Loseto G; Hermine O; Dreyling M; Ruggeri M; Martelli M; Hoster E; Vitolo U;
Br J Haematol; 2019 Jun; 185(5):940-944. PubMed ID: 30407625
[No Abstract] [Full Text] [Related]
59. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
Epperla N; Switchenko J; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Mathews S; Burkart M; Karmali R; Sawalha Y; Hill BT; Ghosh N; Park SI; Bond DA; Hamadani M; Fenske TS; Martin P; Malecek MK; Kahl BS; Flowers CR; Link BK; Kaplan LD; Inwards DJ; Feldman AL; Hsi ED; Maddocks K; Blum KA; Bartlett NL; Cerhan JR; Leonard JP; Habermann TM; Maurer MJ; Cohen JB
Blood Adv; 2023 Jun; 7(11):2287-2296. PubMed ID: 36516079
[TBL] [Abstract][Full Text] [Related]
60. The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.
Hanf M; Chiron D; de Visme S; Touzeau C; Maisonneuve H; Jardel H; Pellat-Deceunynck C; Amiot M; le Gouill S
BMC Cancer; 2016 Oct; 16(1):802. PubMed ID: 27737650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
